Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer

Nana Tchabo, Paulette Mhawech-Fauceglia, Otavia L. Caballero, Jeannine Villella, Amy F. Beck, Anthony J. Miliotto, Jianqun Liao, Christopher Andrews, Shashikant Lele, Lloyd J. Old, Kunle Odunsi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Cancer-embryo antigens or developmentally restricted differentiation antigens (DRDAGs), such as PLAC1 (CT92) and developmental pluripotency associated-2 (DPPA2/CT100), are expressed in pluripotent embryonic cells. They are also recognized as cancer-testis antigens (CT) which are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. These antigens may prove to be markers of 'repopulating' cells with stem cell-like characteristics and could be critical targets for immunotherapy in epithelial ovarian cancer (EOC). Our objective was to define the frequency of expression and immunogenicity of PLAC1 and DPPA2 in EOC and correlate expression with clinical outcome. One-step reverse transcriptase PCR was performed on 101 EOC samples and a panel of normal tissues. Expression of PLAC1 and DPPA2 in the EOC specimens was 21/101 (21%) and 31/101 (31%) respectively. In normal tissues, PLAC1 expression was restricted to the placenta while DPPA2 expression was restricted to the placenta and testis. Immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) were also performed on a subset of specimens. Humoral immunity was demonstrable in 2/12 serum samples from patients whose tumors expressed DPPA2. There was no demonstrable antibody response to PLAC1 in patients with PLAC1 positive tumors. The presence of PLAC1 and DPPA2 did not have a statistically significant effect on recurrence-free and overall survival. The tissue-restricted expression of PLAC1 and DPPA2, their expression in a significant proportion of EOC patients, and their potential to represent markers of stem cells make DRDAGs attractive targets for antigen-specific immunotherapy in EOC.

Original languageEnglish (US)
JournalCancer Immunity
Volume9
StatePublished - Jan 19 2009
Externally publishedYes

Fingerprint

Differentiation Antigens
Serum
Antigens
Immunotherapy
Placenta
Neoplasms
Stem Cells
Testicular Neoplasms
Humoral Immunity
Reverse Transcriptase Polymerase Chain Reaction
Germ Cells
Antibody Formation
Ovarian epithelial cancer
Testis
Embryonic Structures
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Recurrence
Survival
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology
  • Cancer Research

Cite this

Tchabo, N., Mhawech-Fauceglia, P., Caballero, O. L., Villella, J., Beck, A. F., Miliotto, A. J., ... Odunsi, K. (2009). Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immunity, 9.
Tchabo, Nana ; Mhawech-Fauceglia, Paulette ; Caballero, Otavia L. ; Villella, Jeannine ; Beck, Amy F. ; Miliotto, Anthony J. ; Liao, Jianqun ; Andrews, Christopher ; Lele, Shashikant ; Old, Lloyd J. ; Odunsi, Kunle. / Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. In: Cancer Immunity. 2009 ; Vol. 9.
@article{877bc97fef2041e397b29d21adeb64ec,
title = "Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer",
abstract = "Cancer-embryo antigens or developmentally restricted differentiation antigens (DRDAGs), such as PLAC1 (CT92) and developmental pluripotency associated-2 (DPPA2/CT100), are expressed in pluripotent embryonic cells. They are also recognized as cancer-testis antigens (CT) which are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. These antigens may prove to be markers of 'repopulating' cells with stem cell-like characteristics and could be critical targets for immunotherapy in epithelial ovarian cancer (EOC). Our objective was to define the frequency of expression and immunogenicity of PLAC1 and DPPA2 in EOC and correlate expression with clinical outcome. One-step reverse transcriptase PCR was performed on 101 EOC samples and a panel of normal tissues. Expression of PLAC1 and DPPA2 in the EOC specimens was 21/101 (21{\%}) and 31/101 (31{\%}) respectively. In normal tissues, PLAC1 expression was restricted to the placenta while DPPA2 expression was restricted to the placenta and testis. Immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) were also performed on a subset of specimens. Humoral immunity was demonstrable in 2/12 serum samples from patients whose tumors expressed DPPA2. There was no demonstrable antibody response to PLAC1 in patients with PLAC1 positive tumors. The presence of PLAC1 and DPPA2 did not have a statistically significant effect on recurrence-free and overall survival. The tissue-restricted expression of PLAC1 and DPPA2, their expression in a significant proportion of EOC patients, and their potential to represent markers of stem cells make DRDAGs attractive targets for antigen-specific immunotherapy in EOC.",
author = "Nana Tchabo and Paulette Mhawech-Fauceglia and Caballero, {Otavia L.} and Jeannine Villella and Beck, {Amy F.} and Miliotto, {Anthony J.} and Jianqun Liao and Christopher Andrews and Shashikant Lele and Old, {Lloyd J.} and Kunle Odunsi",
year = "2009",
month = "1",
day = "19",
language = "English (US)",
volume = "9",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",

}

Tchabo, N, Mhawech-Fauceglia, P, Caballero, OL, Villella, J, Beck, AF, Miliotto, AJ, Liao, J, Andrews, C, Lele, S, Old, LJ & Odunsi, K 2009, 'Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer', Cancer Immunity, vol. 9.

Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. / Tchabo, Nana; Mhawech-Fauceglia, Paulette; Caballero, Otavia L.; Villella, Jeannine; Beck, Amy F.; Miliotto, Anthony J.; Liao, Jianqun; Andrews, Christopher; Lele, Shashikant; Old, Lloyd J.; Odunsi, Kunle.

In: Cancer Immunity, Vol. 9, 19.01.2009.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer

AU - Tchabo, Nana

AU - Mhawech-Fauceglia, Paulette

AU - Caballero, Otavia L.

AU - Villella, Jeannine

AU - Beck, Amy F.

AU - Miliotto, Anthony J.

AU - Liao, Jianqun

AU - Andrews, Christopher

AU - Lele, Shashikant

AU - Old, Lloyd J.

AU - Odunsi, Kunle

PY - 2009/1/19

Y1 - 2009/1/19

N2 - Cancer-embryo antigens or developmentally restricted differentiation antigens (DRDAGs), such as PLAC1 (CT92) and developmental pluripotency associated-2 (DPPA2/CT100), are expressed in pluripotent embryonic cells. They are also recognized as cancer-testis antigens (CT) which are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. These antigens may prove to be markers of 'repopulating' cells with stem cell-like characteristics and could be critical targets for immunotherapy in epithelial ovarian cancer (EOC). Our objective was to define the frequency of expression and immunogenicity of PLAC1 and DPPA2 in EOC and correlate expression with clinical outcome. One-step reverse transcriptase PCR was performed on 101 EOC samples and a panel of normal tissues. Expression of PLAC1 and DPPA2 in the EOC specimens was 21/101 (21%) and 31/101 (31%) respectively. In normal tissues, PLAC1 expression was restricted to the placenta while DPPA2 expression was restricted to the placenta and testis. Immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) were also performed on a subset of specimens. Humoral immunity was demonstrable in 2/12 serum samples from patients whose tumors expressed DPPA2. There was no demonstrable antibody response to PLAC1 in patients with PLAC1 positive tumors. The presence of PLAC1 and DPPA2 did not have a statistically significant effect on recurrence-free and overall survival. The tissue-restricted expression of PLAC1 and DPPA2, their expression in a significant proportion of EOC patients, and their potential to represent markers of stem cells make DRDAGs attractive targets for antigen-specific immunotherapy in EOC.

AB - Cancer-embryo antigens or developmentally restricted differentiation antigens (DRDAGs), such as PLAC1 (CT92) and developmental pluripotency associated-2 (DPPA2/CT100), are expressed in pluripotent embryonic cells. They are also recognized as cancer-testis antigens (CT) which are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. These antigens may prove to be markers of 'repopulating' cells with stem cell-like characteristics and could be critical targets for immunotherapy in epithelial ovarian cancer (EOC). Our objective was to define the frequency of expression and immunogenicity of PLAC1 and DPPA2 in EOC and correlate expression with clinical outcome. One-step reverse transcriptase PCR was performed on 101 EOC samples and a panel of normal tissues. Expression of PLAC1 and DPPA2 in the EOC specimens was 21/101 (21%) and 31/101 (31%) respectively. In normal tissues, PLAC1 expression was restricted to the placenta while DPPA2 expression was restricted to the placenta and testis. Immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) were also performed on a subset of specimens. Humoral immunity was demonstrable in 2/12 serum samples from patients whose tumors expressed DPPA2. There was no demonstrable antibody response to PLAC1 in patients with PLAC1 positive tumors. The presence of PLAC1 and DPPA2 did not have a statistically significant effect on recurrence-free and overall survival. The tissue-restricted expression of PLAC1 and DPPA2, their expression in a significant proportion of EOC patients, and their potential to represent markers of stem cells make DRDAGs attractive targets for antigen-specific immunotherapy in EOC.

UR - http://www.scopus.com/inward/record.url?scp=74749105337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749105337&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

ER -